Expanding the Patient Pool for Rilonacept

Expanding the Patient Pool for Rilonacept

Recurrent pericarditis complicates 15%-30% of acute pericarditis cases despite initial anti-inflammatory treatment. The RHAPSODY trial (Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis) showed rilonacept, an interleukin-1 cytokine trap, to b...

Full description

Saved in:
Bibliographic Details
Main Authors: Emma St. John, MD, Jessica R. Carey, PharmD, Tanya Wilcox, MD, John Ryan, MD, Satvik Ramakrishna, MD, Anees Daud, MD, Denise Diaz-Robles, PA-C, Adam Smith, PharmD, Kristin Cowan, CPh-T, Libo Wang, MD
Format: Article
Language:English
Published: Elsevier 2025-07-01
Series:JACC: Case Reports
Subjects:
interleukin-1
recurrent pericarditis
rilonacept
Online Access:http://www.sciencedirect.com/science/article/pii/S2666084925005777
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Recurrent pericarditis complicates 15%-30% of acute pericarditis cases despite initial anti-inflammatory treatment. The RHAPSODY trial (Study to Assess the Efficacy and Safety of Rilonacept Treatment in Participants With Recurrent Pericarditis) showed rilonacept, an interleukin-1 cytokine trap, to be an effective therapeutic option for patients with pericarditis recurrence. This case series demonstrates the utility and challenges of rilonacept use in the types of patients excluded from RHAPSODY.
ISSN:2666-0849

Similar Items